Compare · RMD vs TMCI
RMD vs TMCI
Side-by-side comparison of ResMed Inc. (RMD) and Treace Medical Concepts Inc. (TMCI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RMD and TMCI operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.07B, about 127.1x TMCI ($267.9M).
- RMD has been more active in the news (9 items in the past 4 weeks vs 1 for TMCI).
- RMD has more recent analyst coverage (25 ratings vs 19 for TMCI).
- Company
- ResMed Inc.
- Treace Medical Concepts Inc.
- Price
- -
- -
- Market cap
- $34.07B
- $267.9M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 9
- 1
- Recent ratings
- 25
- 19
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Treace Medical Concepts Inc.
Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of device and/or biologic solutions for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was incorporated in 2014 and is headquartered in Ponte Vedra Beach, Florida.
Latest RMD
- SEC Form 4 filed by ResMed Inc.
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.
- Chief Product Officer Leong Justin was granted 6,461 units of ResMed Common Stock, increasing direct ownership by 22% to 35,489 units (SEC Form 4)
- Global General Counsel Rider Michael J was granted 3,230 units of ResMed Common Stock, increasing direct ownership by 34% to 12,718 units (SEC Form 4)
- Chairman and CEO Farrell Michael J. was granted 13,547 units of ResMed Common Stock, increasing direct ownership by 3% to 479,803 units (SEC Form 4)
- Chief Financial Officer Bloomer Aaron was granted 9,072 units of ResMed Common Stock (SEC Form 4)
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
- ResMed upgraded by RBC Capital Mkts with a new price target
Latest TMCI
- Chief Legl & Comp Off, CorpSec Elder Scot Michael covered exercise/tax liability with 25,457 shares, decreasing direct ownership by 3% to 753,226 units (SEC Form 4)
- Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3D® Study Demonstrating Sustained, Positive Outcomes of the Lapiplasty® Procedure
- Chief Executive Officer Treace John T. bought $246,654 worth of shares (55,944 units at $4.41), increasing direct ownership by 0.76% to 7,404,383 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Treace Medical Concepts Inc.
- Chief Innovation Officer Scanlan Sean F. covered exercise/tax liability with 9,814 shares, decreasing direct ownership by 1% to 679,863 units (SEC Form 4)
- Chief Financial Officer Hair Mark covered exercise/tax liability with 37,102 shares, decreasing direct ownership by 4% to 914,900 units (SEC Form 4)
- Chief Legl & Comp Off, CorpSec Elder Scot Michael covered exercise/tax liability with 16,253 shares, decreasing direct ownership by 2% to 778,683 units (SEC Form 4)
- SEC Form 10-Q filed by Treace Medical Concepts Inc.
- Treace Medical Concepts Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Treace Medical Concepts Reports Second Quarter 2026 Financial Results